The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects

Inclusion Criteria: * Read, sign, and date an information consent; * Willing and able to follow instructions and maintain the appointment schedule; * Best-corrected visual acuity of 0.6 logMAR or better in each eye as assessed at Visit 1; * Must not have used any topical ocular drops for approximately 24 hours prior to Visit 1; * Meet protocol-specified criteria for dry eye at Visit 1; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * History or evidence of ocular or intraocular surgery or serious ocular trauma in either eye within the past six months; * Current punctal occlusion of any type (e.g., collagen plugs, silicon plugs); * History of intolerance or hypersensitivity to any component of the study medications; * History or evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye; * Use of any concomitant topical ocular medications during the study period; * Use of systemic medications that may contribute to dry eye unless on a stable dosing regimen for a minimum of 30 days prior to Visit 1; * Ocular conditions such as conjunctival infections, iritis, or any other ocular condition that may preclude the safe administration of either drop under investigation; * Unwilling to discontinue contact lens wear during the study period. Contact lens wear must have been discontinued at least one week prior to Visit 1. * Participation in an investigational drug or device study within 30 days of entering this study; * Other protocol-defined exclusion criteria may apply.